As demand for peptide therapies continues to rise, wellness and aesthetics practices are exploring new opportunities for peptide practice growth. But introducing peptide programs requires more than responding to patient demand. It calls for a clear understanding of regulatory compliance, medical oversight, and operational risk.
In this episode of Skytale Insights, healthcare attorney Shalyn Watkins of Holland & Knight joins the conversation to discuss the evolving landscape of peptide therapies and what practice owners should consider when introducing or expanding these offerings. From peptide programs for med spas to broader wellness services, the discussion highlights the legal, clinical, and operational considerations that can influence sustainable growth.
The conversation explores peptide sourcing, compounding pharmacies, third-party testing, liability, and insurance coverage, offering perspective on peptide therapy risk management and the foundations of a responsible peptide therapy business. Drawing parallels to compounded GLP-1 medications and artificial intelligence adoption, the episode also examines why patient demand alone isn’t a growth strategy and how practices can balance innovation with long-term wellness practice growth.
This episode is for informational purposes only and does not constitute legal or medical advice. Regulatory developments discussed reflect the time of recording.
Key topics discussed include:
- The evolving regulatory landscape for peptide therapies
- Medical oversight and compliance considerations for wellness and aesthetics practices
- Peptide sourcing, compounding pharmacies, and third-party testing
- Liability, insurance, and peptide therapy risk management
- Operational readiness and sustainable peptide practice growth
- Lessons from compounded GLP-1 medications and emerging healthcare innovations